Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Multicenter Double-Blind Randomized Split-Face Study to Evaluate Revanesse® Ultra vs Restylane® for Correction of NLF

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02987205
Recruitment Status : Completed
First Posted : December 8, 2016
Results First Posted : December 13, 2017
Last Update Posted : February 22, 2018
Sponsor:
Information provided by (Responsible Party):
Prollenium Medical Technologies Inc.

Brief Summary:
A randomized, multicenter, double blind, split-face study in subjects seeking NLF correction. Subjects were treated with Revanesse Ultra in the NLF on one side of the face and Restylane in the NLF on the other side of the face. The side of the face for each product was randomly assigned. The investigator performing the evaluations and the subject were blinded to the treatment; injections of the study product were performed by an unblinded injecting investigator.

Condition or disease Intervention/treatment Phase
Nasolabial Fold Correction Device: Revanesse Ultra Device: Restylane Not Applicable

Detailed Description:
The study was a randomized, double-blind prospective, comparative study of the efficacy and safety of Revanesse Ultra versus the approved product Restylane in the cutaneous correction of NLFs. Randomization followed a 1:1 within-subject control model of augmentation correction of NLFs. Given that the implants have been shown to not migrate, the within-subject model was ideal and had already been shown in previous studies to detect differences. Subjects with signs of NLFs who met the entry criteria were enrolled. All subjects were followed for efficacy and safety for 6 months. Subjects could have open-label retreatment as needed with Revanesse Ultra at 6 months if their baseline WSRS scores had returned to baseline, or as needed to achieve optimal correction if their baseline WSRS scores had not returned to baseline and were followed for a total of 12 months. The study design was appropriate for the indication studied.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 163 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Double-Blind, Randomized, Split-Face Study to Evaluate the Safety and Efficacy of Revanesse® Ultra Versus Restylane® for the Correction of Nasolabial Folds
Study Start Date : May 2015
Actual Primary Completion Date : March 2016
Actual Study Completion Date : September 2016

Arm Intervention/treatment
Experimental: Revanesse Ultra
Revanesse Ultra in the NLF on one side of the face
Device: Revanesse Ultra
NLF correction

Active Comparator: Restylane
Restylane injection in the NLF on the other side of the face to optimal correction
Device: Restylane
NLF Correction




Primary Outcome Measures :
  1. Primary Efficacy Variable is Change From Baseline to Visit 6/Week 24 in Wrinkle Severity Rating Scale (WSRS) Score [ Time Frame: Visit 6/Week 24 ]

    Primary efficacy variable is change from Baseline to Visit 6/Week 24 in Wrinkle Severity Rating Scale (WSRS) - Treatment success is defined as at least a 1-grade improvement in WSRS from baseline to Week 24

    WSRS Score categories:

    1. Absent - No visible fold; continuous skin line.
    2. Mild - Shallow but visible fold with a slight indentation; minor facial feature; implant is expected to produce a slight improvement in appearance.
    3. Moderate - Moderately deep folds; clear facial feature visible at normal appearance but not when stretched; excellent correction is expected from injectable implant.
    4. Severe - Very long and deep folds; prominent facial feature; less than 2 mm visible when stretched; significant improvement is expected from injectable implant.
    5. Extreme - Extremely deep and long folds, detrimental to facial appearance; 2 to 4 mm visible V-shaped fold when stretched; unlikely to have satisfactory correction with injectable implant alone.


Secondary Outcome Measures :
  1. Secondary Efficacy Endpoints Are the Responder Rate, Percentage of *Nasolabial Folds* With Treatment Success [ Time Frame: Visit 6/Week 24 ]

    Treatment success (defined as at least a 1-grade improvement in WSRS from baseline to Week 24):

    The WSRS Score is a 5-point scale. The WSRS score was assessed for each NLF at every study visit through Visit 6/Week 24 by a blinded evaluator (blinded to the treatment assignment of each NLF).



Other Outcome Measures:
  1. Other Efficacy Variables Include Change in WSRS Score [ Time Frame: Visit 2/Week 1, Visit 3/Week 2, Visit 4/Week 4, and Visit 5/Week 12 ]
    Treatment success is (defined as at least a 1-grade improvement in WSRS from baseline to Week 24)

  2. Other Efficacy Variables Include Change in Patient Global Aesthetic Improvement (pGAI) Score [ Time Frame: Visit 2/Week 1, Visit 3/Week 2, Visit 4/Week 4, and Visit 5/Week 12 ]
    Treatment success is (defined as at least a 1-grade improvement in WSRS from baseline to Week 24)

  3. Other Efficacy Variables Include Change in Investigator Global Aesthetic Improvement (iGAI) Score [ Time Frame: Visit 2/Week 1, Visit 3/Week 2, Visit 4/Week 4, and Visit 5/Week 12 ]
    Treatment success is (defined as at least a 1-grade improvement in WSRS from baseline to Week 24)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   22 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Subjects must meet all of the following criteria to be eligible for the study:

  1. Men or women 22 years of age or older.
  2. Two fully visible bilateral nasolabial folds each with a Wrinkle Severity Rating Scale Score of 3 or 4 that may be corrected with an injectable dermal filler.
  3. If female and of childbearing potential, a negative urine pregnancy test and agree to use adequate contraception. Female subjects of childbearing potential (excluding women who are surgically sterilized or postmenopausal for at least 2 years) must have a negative urine pregnancy test and must be willing to use a medically accepted method of contraception during the study. The following are considered acceptable methods of birth control for the purpose of this study: oral contraceptives, contraceptive patches, contraceptive implant, vaginal contraceptive, double barrier methods (e.g., condom and spermicide), contraceptive injection (Depo-Provera®), intrauterine device (IUD), hormonal IUD (Mirena®), and abstinence with a documented second acceptable method of birth control if the subject becomes sexually active. Subjects entering the study who are on hormonal contraceptives must have been on the method for at least 90 days prior to the study and continue the method for the duration of the study. Subjects who had used hormonal contraception and stopped must have stopped no less than 90 days prior to Visit 1/Day 1.
  4. Ability to understand and comply with the requirements of the study.
  5. Willingness and ability to provide written informed consent.
  6. Agree to refrain from seeking other treatment for this condition during the study.

    -

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from the study:

  1. Wrinkle Severity Rating Scale Score of ≤ 2 on the right or left nasolabial fold.
  2. Women who are pregnant or lactating.
  3. Received prior dermabrasion, facelift, or Botox below the orbital rim within 6 months (180 days) prior to entry into the study.
  4. Previous tissue augmentation (bulking agents) for facial wrinkles and scars within 6 months (180 days) at the proposed injection sites.
  5. Previous tissue augmentation with permanent implants.
  6. Evidence of scar-related disease or delayed healing activity within the past 1 year.
  7. Scars at the intended treatment sites.
  8. History of keloid formation or hypertrophic scars.
  9. Any infection or wound on the face.
  10. Allergic history including anaphylaxis or multiple severe allergies to natural rubber latex or lidocaine.
  11. Aspirin or nonsteroidal anti-inflammatory drugs within 1 week (7 days) prior to treatment.
  12. Concomitant anticoagulant therapy, antiplatelet therapy, or history of bleeding disorders or connective tissue disorders.
  13. Over-the-counter (OTC) wrinkle products or prescription wrinkle treatments within 4 weeks (28 days) prior to treatment and throughout the study.
  14. Immunocompromised or immunosuppressed.
  15. Clinically significant organic disease including clinically significant cardiovascular, hepatic, pulmonary, neurologic, or renal disease or other medical condition, serious intercurrent illness, or extenuating circumstance that, in the opinion of the investigator, preclude participation in the trial.
  16. Received any investigational product within 30 days of signing the Informed Consent Form.
  17. Facial tattoo that may interfere with diagnosis.
  18. Systemic (oral/injectable) corticosteroids or immunosuppressive medications within 30 days prior to treatment and topical steroids on the face within 14 days prior to treatment start and throughout the study.

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02987205


Sponsors and Collaborators
Prollenium Medical Technologies Inc.
Investigators
Layout table for investigator information
Principal Investigator: Michael H Gold, MD Tennessee Clinical Research Center
  Study Documents (Full-Text)

Documents provided by Prollenium Medical Technologies Inc.:
Study Protocol  [PDF] October 28, 2015

Layout table for additonal information
Responsible Party: Prollenium Medical Technologies Inc.
ClinicalTrials.gov Identifier: NCT02987205    
Other Study ID Numbers: SYM2014-02
First Posted: December 8, 2016    Key Record Dates
Results First Posted: December 13, 2017
Last Update Posted: February 22, 2018
Last Verified: November 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Device Product: Yes